SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is experiencing intense volatility and downward pressure after Marvell canceled its purchase orders, citing a confidentiality breach caused by the CFO's recent public commentary. Community members are deeply divided between long-term bulls who believe in the company's underlying photonics technology and frustrated investors who are calling for management accountability and questioning the firm's transparency after news of the cancellation was delayed.

Lucid Group, Inc. manufactures electric vehicles. It designs, develops, and builds energy storage systems for electric vehicles and supplies automakers with the battery pack system needed to power hybrid, plug-in, and electric vehicles. The company was founded in December 2007 and is headquartered in Newark, CA.

Lucid Group Inc

Lucid Group is trending as investors grapple with persistent downward pressure and concerns over potential dilution, despite the company's focus on its upcoming mid-size vehicle platform and continued financial backing from key institutional partners. Community sentiment remains sharply divided between long-term bulls highlighting the company's technical product advantages and skeptics who fear further share price erosion and the threat of bankruptcy or restructuring.

Erasca, Inc. is a clinical stage precision oncology company. It focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. It has assembled a wholly owned or controlled RAS/MAPK pathway focused pipeline comprising modality-agnostic programs. The company was founded by Jonathan E. Lim and Kevan Shokat on July 2, 2018 and is headquartered in San Diego, CA.

Erasca Inc

Erasca (ERAS) is facing significant market volatility following an 8-K filing that disclosed a Grade 5 fatality, raising investor concerns regarding potential FDA clinical holds and long-term asset viability. Community sentiment is deeply polarized, with critics warning of toxic data and potential bankruptcy, while some long-term holders dismiss the reaction as an over-correction and advocate for buying the dip.

Lightwave Logic, Inc. is a development stage company which engages in the commercialization of electro-optic photonic devices. The firm offers the P2ICTM technology platform which uses in-house proprietary organic polymers. Its products include electro-optical modulation devices and proprietary polymer photonic integrated circuits. The company was founded on June 24, 1997 and is headquartered in Englewood, CO.

Lightwave Logic Inc

Lightwave Logic is trending as investors bet on the commercial viability of its proprietary Perkinamine polymer technology, which is seen as a key solution for high-speed, energy-efficient data center and AI connectivity. Community discussions are heavily focused on the company's potential to displace legacy materials in hyperscale environments, with significant excitement surrounding upcoming industry milestones and partnerships.

Our vision is to create a global exchange using Ethereum blockchain, where everyone on this planet has the opportunity to buy and sell mobile bandwidth in any country just like you buy foreign currencies on FOREX.

DENT

DENT is currently capturing community attention as investors debate its potential for a breakout, with many highlighting its utility in the mobile data space and active development as catalysts for future growth. The community sentiment remains polarized, featuring a mix of long-term holders waiting for a significant price movement and vocal skeptics labeling the asset as a speculative pump-and-dump opportunity.

Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

Intellia Therapeutics Inc

Intellia Therapeutics is currently at the center of intense market attention following the release of positive Phase 3 data for its gene-editing therapy and the initiation of a rolling FDA filing. The stock is experiencing extreme volatility as retail investors debate the significance of the clinical results and the implications of a subsequent common stock offering, while the community remains sharply divided over the potential for a short squeeze given the high short interest.

Joby Aviation, Inc. is a transportation company, which engages in developing an all-electric, vertical take-off and landing aircraft that intends to operate as a commercial passenger aircraft. The company was founded by Bevirt Joebenn in 2009 and is headquartered in Santa Cruz, CA.

Joby Aviation Inc

Joby Aviation is trending as the community highlights the recent completion of point-to-point electric air taxi demonstration flights in New York City, which serves as a major real-world proof point for urban air mobility. Investors are actively debating the company's transition from prototype testing to infrastructure integration, with sentiment split between those focused on long-term growth catalysts and those concerned by ongoing execution challenges and stock price volatility.

X-Energy, Inc. operates as an energy company The firm focuses on modular nuclear reactors and fuel technology for clean energy generation. The company was founded by Kam Ghaffarian and Eben Mulder on 2009 and is headquartered in Rockville, MD.

X-Energy Inc. - Ordinary Shares- Class A

X-energy Inc

X-energy is generating significant investor buzz following its recent IPO, fueled by strong backing from major players like Amazon and interest in its role within the burgeoning AI data center power narrative. The community is actively debating the company's valuation and long-term execution capabilities compared to other nuclear-sector peers.

Revolution Medicines, Inc. is a clinical-stage precision oncology company, which engages in developing novel targeted therapies. It engages in the discovery and development of cancer treatment by pioneering novel combination and monotherapy treatment regimens to maximize the depth and durability of clinical benefit and circumvent adaptive resistance mechanisms for patients which are dependent on the RAS and mTOR pathway. The company was founded by Mark A. Goldsmith, Kevan Shokat, Martin D. Burke, David L. Pompliano and Michael Fischbach in October 2014 and is headquartered in Redwood City, CA.

Revolution Medicines Inc

Revolution Medicines is trending as investors digest news of potential acquisition interest from Merck, following earlier volatility spurred by a false buyout rumor involving AbbVie. The market is closely monitoring this high-conviction biotech play as institutional interest remains strong around its RAS-inhibitor pipeline.

Trulieve Cannabis Corp. engages in the provision of medical cannabis products and services. It cultivates and produces its products in-house and distributes to its branded stores, as well as directly to patients via home delivery. The company was founded by Kim Rivers & Jason Pernell on September 17, 1940 and is headquartered in Tallahassee, FL.

Trulieve Cannabis Corp - Ordinary Shares (Sub Voting)

Trulieve Cannabis

Trulieve Cannabis is trending as the market reacts to the formal rescheduling of medical marijuana to Schedule III, a shift expected to provide significant tax relief by eliminating the Section 280E tax burden. Community discourse remains heavily focused on the company's dominant market share in Florida and anticipation that this regulatory milestone will pave the way for institutional capital and potential uplisting to major exchanges.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Q1 Earnings Estimate for PARK Issued By Northland Securities

Park Dental Partners, Inc. (NASDAQ:PARK - Free Report) - Equities research analysts at Northland Securities decreased their Q1 2026 earnings per share estimates for shares of Park Dental Partners in...

Park Dental Partners Q4 Earnings Call Highlights

Park Dental Partners (NASDAQ:PARK) used its fourth-quarter and full-year 2025 earnings call to highlight a record year for revenue and adjusted EBITDA, discuss its early-December IPO, and outline a...

Park Dental Partners (NASDAQ:PARK) Announces Earnings Results, Beats Expectations By $0.37 EPS

Park Dental Partners (NASDAQ:PARK - Get Free Report) posted its quarterly earnings data on Wednesday. The company reported $0.30 earnings per share for the quarter, beating analysts' consensus...

What is Northland Capmk's Forecast for PARK FY2025 Earnings?

Park Dental Partners, Inc. (NASDAQ:PARK - Free Report) - Northland Capmk issued their FY2025 earnings estimates for shares of Park Dental Partners in a report issued on Monday, January 5th. Northland...

Park Dental Partners (NASDAQ:PARK) Now Covered by Analysts at Northland Securities

Northland Securities started coverage on Park Dental Partners in a report on Monday. They issued an "outperform" rating and a $21.50 target price on the stock...

Park Dental Partners, Inc.'s (NASDAQ:PARK) Quiet Period Set To Expire on January 12th

Park Dental Partners' (NASDAQ:PARK - Get Free Report) quiet period will end on Monday, January 12th. Park Dental Partners had issued 1,535,000 shares in its public offering on December 3rd. The total...

Park Dental Partners, Inc. Announces Closing of Initial Public Offering

Park Dental Partners, Inc. (Park Dental Partners or the Company), today announced the closing of its initial public offering of 1,535,000 shares of its common stock at a price to the public of $13.00...

Park Dental Partners, Inc. engages in the provision of comprehensive business support services including clinical team members, administrative personnel, facilities and equipment. The company was founded by Gregory T. Swenson and Brian Murn in 1972 and is headquartered in Roseville, MN.

Current Price	$18.22
Prev Close	$17.95
Open	$17.90
Dividend Yield	0.00%
50-Day Moving Average	$17.86
Beta	1.00
Avg. Volume	41,598.64
PE Ratio	N/A

52-Week High	$21.60
52-Week Low	$9.53
Market Capitalization	$81.05M
EPS (Annual)	-$0.0843
Price to Book	3.55
Revenue Per Employee	$201,727.72

PARK
Park Dental Partners Inc.

Feed

News

Sentiment

Fundamentals

Info

Latest PARK News

PARKPark Dental Partners Inc.